CAJ | 학술논문

目的探讨阿糖胞苷（Ara- C）联合氟达拉滨（Flu）组成的改良FLAG方案治疗难治性急性髓系白血病(AML)患者的疗效及安全性。方法采用改良FLAG方案治疗难治性AML患者14例，其中原发难治性AML 8例，复发难治性AML 6例。具体方案为氟达拉滨（Flu）30mg/（m2·d），静脉滴注，d1~5；阿糖胞苷（Ara- C）1g/（m2·d），静脉滴注，d1~5；粒细胞集落刺激因子（G- CSF）5μg/（kg·d），皮下注射，d0~5。结果治疗1个疗程后，14例患者中7例获得完全缓解（CR），CR率50％；2例部分缓解（PR），PR率14.3%；5例未缓解（NR）；总有效率（CR+PR）为64.3%。无一例治疗相关性死亡。结论改良FLAG方案是治疗难治性AML的有效方案，且安全性良好。
목적탐토아당포감（Ara- C）연합불체랍빈（Flu）조성적개량FLAG방안치료난치성급성수계백혈병(AML)환자적료효급안전성。방법채용개량FLAG방안치료난치성AML환자14례，기중원발난치성AML 8례，복발난치성AML 6례。구체방안위불체랍빈（Flu）30mg/（m2·d），정맥적주，d1~5；아당포감（Ara- C）1g/（m2·d），정맥적주，d1~5；립세포집락자격인자（G- CSF）5μg/（kg·d），피하주사，d0~5。결과치료1개료정후，14례환자중7례획득완전완해（CR），CR솔50％；2례부분완해（PR），PR솔14.3%；5례미완해（NR）；총유효솔（CR+PR）위64.3%。무일례치료상관성사망。결론개량FLAG방안시치료난치성AML적유효방안，차안전성량호。
Objective To investigate the efficacy and safety of modified FLAG regimen in treatment of refractory acute myeloid leukemia (AML). Methods Fourteen patients with refractory AML, including 8 cases of primary refractory AML and 6 cases of relapsed refractory AML, were treated with modified FLAG regimen consisting of fludarabine (Flu) 30mg/ (m2·d), d1~5, cytarabine (Ara- C)1g/ (m2·d), d1~5, granulocyte colony- stimulating factor (G- CSF) 5μg/ (kg·d), d0~5. Results There were 7 cases of complete remission(CR), 2 cases of partial remission(PR) and 5 patients had no response(NR) in this series, with a CR rate of 50.0% and an overal response rate of 64.3%. Conclusion The modified FLAG regimen is safe and effective for treatment of refractory AML.